Novartis AG – FDA Approval for Cosentyx in Pediatric Hidradenitis Suppurativa
Novartis AG, a Swiss pharmaceutical company listed on the SIX Swiss Exchange, announced that its biologic therapy Cosentyx (secukinumab) has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS). The decision follows the publication of pivotal Phase‑III trial data demonstrating clinically meaningful symptom improvements in this patient population.
Key Details of the FDA Approval
| Item | Information |
|---|---|
| Drug | Cosentyx (secukinumab) |
| Indication | Pediatric patients ≥12 yrs with moderate to severe hidradenitis suppurativa |
| Regulatory Body | U.S. Food and Drug Administration (FDA) |
| Approval Source | Novartis press release and public statements (2026‑03‑13) |
| Market Impact | Provides an additional therapeutic option for a condition that often manifests in adolescence, potentially expanding the drug’s commercial reach in the United States. |
Context Within Novartis’ Portfolio
- Cosentyx is one of Novartis’ high‑volume products, with a reported quarterly sales figure of CHF 1.807 million immediately preceding the announcement.
- The approval complements Novartis’ broader strategy of expanding the use of its biologics across age groups and disease indications, reinforcing its position as a leading developer of transformative treatments in areas of significant medical need.
Market and Investor Reactions
- The Swiss stock market recorded a stable closing on Friday, 13 March 2026, with the Swiss Market Index (SMI) holding its position amid broader European volatility. The approval of Cosentyx is expected to reinforce investor confidence in Novartis’ pipeline, potentially supporting the company’s share price, which closed at CHF 121.36 on 12 March 2026.
- Novartis’ market capitalization stands at CHF 286.84 billion, and the company’s price‑earnings ratio is 21.66.
Regulatory and Clinical Significance
- Hidradenitis suppurativa is a chronic inflammatory skin disorder that can lead to painful nodules and scarring. Current treatment options for children and adolescents are limited, making this FDA approval a significant advance in patient care.
- The approval aligns with FDA guidelines that encourage expanded access to effective biologics for pediatric populations when clinical evidence supports safety and efficacy.
Outlook
Novartis is likely to pursue additional pediatric indications for Cosentyx, given its success in this new therapeutic area. Continued monitoring of post‑marketing data and real‑world effectiveness will be essential to confirm long‑term benefits and safety profiles in younger patients.
This article is based exclusively on the information provided in the supplied financial news excerpts and company fundamentals.
